Abstract： Objective To investigate the 3-year survival rate of patients with advanced non-small cell lung cancer who received cisplatin combined with gemcitabine chemotherapy. Methods A retrospec-tive study was performed on 86 cases of patients with advanced non-small cell lung cancer who were admit-ted from March 2014 to March 2015. Patients were randomly divided into the gefitinib combined treatment group,43 cases,including 23 male and 20 female,aged(58. 7 ± 10. 93) years old,ranged from 44 to 73 years old; the gemcitabine combined treatment group,43 cases, including 25 male and 18 female, aged (61. 8 ± 7. 44)years old,ranged from 46 to 72 years old. The gemcitinib combined treatment group of pa-tients was treated with cisplatin combined chemotherapy,and the gemcitabine combined treatment group was treated with gemcitabine combined cisplatin chemotherapy. The clinical efficacy,incidence of adverse reac-tions,recurrence rate,metastasis rate,survival rate and quality of life of the patients in the two groups were compared. Results The total effective rate[86. 1% (37/43)]in the gemcitabine combined treatment group was higher than that in the gemcitabine combined treatment group[69. 8% (30/43)],and the incidence of adverse reactions [6. 9% (3/43)] in the gemcitabine combined treatment group was lower than that in the gemcitabine combined treatment group [18. 4% ( 8/43 )], with statistically significant differences ( P <0. 05). The recurrence rate and metastasis rate of patients in the gemcitabine combined treatment group [4. 6% (2/43),2. 3% (1/43)] were lower than those in the gemcitabine combined treatment group [16. 3% (7/43),14. 0% (6/43)];the survival rate [55. 8% (24/43)] in the gemcitabine combination treatment group was higher than that in the gemcitabine combination treatment group [34. 9% (15/43)];the mean survival time(22. 23 ± 1. 24)months in the gemcitabine combined treatment group was longer than that in the gemcitabine combined treatment group(18. 23 ± 1. 34)months,and the difference was statistical-ly significant(P<0. 05). The scores of physiology,daily life,cognition,emotion,social function and overall health status in the gemcitabine combined treatment group were all higher than those in the gemcitabine combined treatment group during the follow-up period,and the differences were statistically significant(P<0. 05). Conclusion Cisplatin combined with gefitinib in the treatment of advanced NSCLC is more effec-tive,which can achieve better survival rate during the follow-up,and the side effects of chemotherapy will not be increased during the treatment,so the safety is higher.